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Abstract
Clinical depression and distress are prevalent in cancer patients and are often
unrecognized by clinicians. However, patient-reported outcomes, or PROs, can facilitate
provider assessment of oncology treatment plans by detecting depressive and distress symptoms
early in a patient’s cancer trajectory. Since PROs capture patients’ subjective experience, they
provide invaluable insight into patient satisfaction, quality of life, and mental health. In April
2019, leadership at Smilow Cancer Hospital at Yale New Haven Health implemented a new,
electronic workflow that widely disseminated PHQ-9 and NCCN Distress questionnaires to
patients seen in three Smilow Cancer Hospital Care Centers. The objective of this pilot study was
to improve early detection of depression and distress in cancer patients through PROs.
Prevalence of distress, depression, and self-harm was analyzed across age, sex, race, gender,
time since diagnosis, and cancer center, and statistically significant differences were validated
with a chi-square analysis. 18.6% of patients had positive distress and 5.3% had positive PHQ-9
Scores indicating depression. For those with depression, 1.67%, 1.69%, 0.92%, and 0.34% had
mild, moderate, moderately severe, and severe depression, respectively. All patients were
referred to appropriate interventions. Additionally, an unconditional logistic regression was
performed to understand significant predictors of self-harm and suicidal ideation. 1.00% of
patients suffered from suicidal ideation and self-harm. Moderately severe depression and severe
depression were statistically significant predictors for self-harm. Moreover, this study recognized
clinical distress and depression and provided interventions to these patients. Future
implementation of PROs of distress and depression surveys in cancer patients should consider
incorporating culturally sensitive questions, acknowledging language barriers, and making
accommodations for patients with cognitive impairments.
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Introduction:
There has been a greater emphasis on patient centricity and the patient's role in his or her
medical care in recent years. Patient centricity is measured through patient-reported outcomes
(PROs), defined as any report of the status of a patient's health condition that comes directly
from the patient without interpretation of the patient's response by a clinician or anyone else. 1
Essentially, PROs capture how patients feel about their treatment, well-being, and symptoms.

PROs have garnered medical providers' attention for their beneficial effects on patient health,
such as improving quality of life (QoL) and treatment-related side effects.2 Thus, it is
recommended that PROs be implemented into routine cancer care.
Compared to its peak in the 1990s, cancer mortality has been steadily decreasing in the
United States due to advancing medical treatments and early cancer screening programs, leading
to improved survivorship in cancer patients.3 Cancer mortality has decreased continuously from
1991 to 2018 for a total decline of 31%, translating into 3.2 million fewer cancer deaths.4 Given
that most cancers have transitioned from acute, life-threatening diseases to chronic ones, there
has been growing concern with the application of PROs, such as distress and depression
screenings, to improve post-cancer care since prolonged cancer prognosis does not necessarily
equal better QoL. Although distress and depression screenings have been validated and widely
disseminated in family care practices5, the uptake of screening tools for the psychological care
and intervention of oncology patients has not been fully integrated into most cancer centers.
Hence, to improve oncology care, payers have implemented hospital mandates to screen for
distress and depression in cancer patients to improve health and alleviate costs 6.
Given that the 5 year-relative survival from cancer is 67.4%, approximately 25% of
cancer patients suffer from clinical depression after receiving a cancer diagnosis, fearing death,
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recurrence, and treatment side effects.7 Unfortunately, clinicians often dismiss serious,
depressive symptoms in cancer patients, assuming sadness and depression are part of the normal,
emotional repertoire of oncology patients.8 Although it is expected for cancer patients to feel
saddened about their diagnosis, clinical depression and distress are categorically different from
temporary sadness and require immediate psychological intervention.9 Sadness is a normal
human emotion that fluctuates over time and can be appropriately managed with strong family
support and/or lifestyle changes; however, cancer patients suffering from clinical depression
suffer from physical and psychological symptoms that significantly impair their quality of life
for a prolonged period.10 About 70% of depressed cancer patients do not receive appropriate
help, and only 5% of patients consult a medical professional.11 Suicide risk in cancer patients is
four times higher than in the general population, and this risk is the highest in the first year of
diagnosis.12 Moreover, the incidence of suicide death in cancer patients was 39.72 per 100,000
person-years.13 Therefore, PROs are crucial for detecting depression and distress in a timely and
accurate manner so that patients’ QoL and survivorship improves. PROs also glean incredible
insight on how depression and distress scores, as well as important factors like cancer subtype,
age, sex, and gender, may affect a patient’s thought of self-harm throughout his or her cancer
trajectory. Hence, if appropriately utilized, PROs of distress and depression screenings could
improve cancer patients' mental health by referring them to social workers, psychologists, or
psychiatrists for appropriate interventions and offer holistic patient-centric care.
The driving motivation for collecting PROs in oncology patients stems from the Center
for Medicare and Medicaid Innovation (CMMI) incentivizing distress and depression screenings
in routine medical care via the oncology care model (OCM), a program that improves patient
health while minimizing healthcare expenditures.14 OCM encourages a multidisciplinary
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approach to healthcare by mandating the use of social workers, who can assist cancer patients in
an array of supportable services like financial and nutritional support. Among the 13 care
components enlisted by the OCM framework, two of them require the involvement of social
work services: Advance care plans and Distress and Depression screening. 15 The latter mandate
encourages clinicians to address patients' psychosocial health needs in a holistic manner while
ensuring cancer patients are receiving necessary help. Ultimately, OCM is a payment model that
tethers financial rewards to provider accountability and proper cancer patient management. The
OCM framework incentivizes systematic efficiency in care centers by providing additional
payments in 6-month increments for each active cancer patient and encouraging a savings
program for chemotherapies and drugs if overall costs are lowered.14
As of January 2020, 138 practices are participating in OCM, with the Smilow Cancer
Hospital at Yale-New Haven Health (YNHH) being one of the four participating care centers in
Connecticut.16 Within the Smilow Cancer Hospital, the OCM performance metric accounts for
the number of patients appropriately screened and followed up within 24 hours, which results in
bonus payments—this Pay for Performance model rolled-out in January 2019. Thanks to these
financial incentives, cancer care centers within the YNHH network have piloted the collection of
distress and depression PROs within the electronic medical record workflow.
Prior to the initiation of this new electronic PRO process in 2018 at Smilow Cancer
Hospital and Care Centers, depression and distress screening had low compliance rates due to a
lack of standardized workflow. Screenings were done on paper, not collected from all patients,
and were not patient-reported. In turn, compliance rates for completed the surveys were low:
26% for depression screening and 40% for distress. Additionally, depression and distress

8

screenings were not patient-reported since the depression and distress questionnaires were
completed by an OCM Care Coordinator and a nurse, respectively.
The purpose of this study was to determine the feasibility of implementing the distress
and depression PROs via the electronic medical record in three Smilow Cancer Hospital Care
Centers and examining differences in depression and distress by various demographic and
clinical characteristics. These analyses will provide preliminary results of feasibility, rates of
depression and distress, and referrals for treatment. These findings will provide necessary
information for disseminating and implementing these PROs and improving early detection of
depressive and distress symptoms.

Methods:
Overview of Project
In November 2018, we conducted a pilot program that electronically screened all
ambulatory cancer patients for distress and depression symptoms at three Smilow Cancer
Hospital Cancer Care sites: The Smilow Cancer Hospital Breast Center, Guilford Care Center,
and the Care Center at Torrington. The study was conducted in multiple phases, with a
preparatory phase beginning in November 2018 and the remaining two phases of roll-outs
beginning in April 2019 and August 2019. Smilow Breast Center and Guilford went live in April
2019, and Torrington Care Center followed in August 2019. The study continued until March
2020. At these study sites, patients completed the PHQ-2 and PHQ-9 surveys and Distress
Thermometer screening on iPads while in the waiting room, who were then alerted in real-time
by providers regarding referrals and interventions. Also, in compliance with the new Joint
Commission mandate, the YNHH screen policy implemented the Columbia Suicide Severity
Rating Scale (CSSRS) to assess patients with suicide ideation.
9

Patients
The scope of the program included all adult patients diagnosed with cancer who were
seen for a clinic visit at Smilow, Guilford, and Torrington Care Centers. Patients who were seen
for imaging or procedure visits were not assigned the surveys.

Data Collection
Information on patient age, sex, race, gender, diagnosis dates, PHQ-9, PHQ-2, and
distress scores were collected from EPIC electronic medical records provided by the JDAT team
at Yale New Haven Health.

PHQ-2, PHQ-9 and CRRS Questionnaires
The PHQ-2 is a 2-question survey that acts as the first-line approach for depression and
anhedonia screening over the past two weeks.17 The PHQ-2 score ranges from 0-6: If a patient
scores a 3 or higher, then a major depressive episode may likely occur. Patients who screen
positive for depression should complete the PHQ-9 to determine if they are at risk for a
depressive disorder.17 However, if the patient scores a 3 or less on the PHQ-2 survey, the patient
has a negative depression score which does not necessitate an intervention (Figure 1).
The PHQ-9 is a 9-question survey that measures depression severity, with the first two
questions stemming from the PHQ-2. Scores of 1-4, 5-9, 10-14, 15-19, and 20-27 act as
thresholds for minimal, mild, moderate, moderately severe, and severe depression, respectively. 18
Minimal depression does not necessitate an intervention. The last question on the survey screens
for suicide risk and self-harm, which requires emergency assessment and intervention. This
question asks: "Thoughts that you would be better off dead or thoughts of hurting yourself in
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some way?" If patients answer with "several days", "more than half the days", or "nearly every
day", then they must remain in the clinic and have a social worker evaluate them with the
Columbia Suicide Severity Rating Scale (CSSRS).19 The CSSRS is an evidence-based tool that
assesses suicidal ideation. For patients who screen positive for suicidal ideation (moderate or
high) then a suicide risk assessment is done by a healthcare provider or a social worker, who then
asks about the patient's plan, intent, or self-harm behaviors. If the patient is considered high risk
of suicide, a healthcare provider, social worker, or nurse must stay with the patient until he or she
is transferred to the emergency department (Figure 1).
Under the "Preventive Care and Screening: Screening for Depression and Follow-Up
Plan" of the Oncology Care Model, a percentage of cancer patients 18 years and older who were
screened for depression every 6 months upon their first encounter and if screened positive,
should pursue follow up. Follow-up plans include suicide risk assessment, referral to a
practitioner for the treatment of depression, pharmacological interventions, and more.20

The National Comprehensive Cancer Network (NCCN) Distress Thermometer
Distress is measured through the National Comprehensive Cancer Network (NCCN)
Distress Thermometer, an evidence-based tool that helps providers provide support to oncology
patients.21 The tool measures distress from a score of 0-10, and if patients report a score greater
than or equal to four, which indicates moderate to extreme distress, clinical judgment is required,
and a physician will be notified of the score. If the patient scores a 4 or lower on the NCCN
distress questionnaire, the patient has negative distress and does not require an intervention;
however, if a distress score of 4 or more is recorded, then based on the score on the Distress
Screening tool, referrals could be made to a social worker, chaplain, nutritionist, or psychiatrist. 22
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(Figure 1). Although distress screening must be assessed at a minimum of one time, all patients
should be screened at every medical visit. If this is not possible, patients should be screened at
their first visit and at appropriate, timely intervals per the NCCN guidelines.23 Also, according to
the Commission on Cancer, all cancer patients must be screened for distress a minimum of once
per pivotal medical visit as determined by the program.24

Current Workflow
When a patient arrives at check-in, the staff determines if they need to complete distress
and depression surveys based on their department-appointed reported visit or DAR.
Questionnaires are administered on the first visit and then every 90 days after the initial visit.
Staff at the front desk are trained to answer questions patients may have regarding the screening
program, such as “Who will receive the results?” and “What is this used for?” If asked these
questions, the staff will answer “Your Smilow care prover team”, and “To better meet your
physical and emotional needs'', respectively. Once they agree to complete the screening, the
patient completes the Distress Screening and PHQ-2 on the iPad; if the patient screens positive
on the PHQ-2 survey, then they will complete the PHQ-9. If the patient refuses to answer the
questionnaire, the front desk will document it through the DAR. Options for non-participation
include language barriers, technology issues, lack of an iPad, and general refusal. If the distress
and depression screenings are negative (distress ≤ 4 and PHQ-2 < 3), the results are filed and no
intervention is necessary. If the screening is positive (distress ≥ 4 and/or positive PHQ-2 ≥ 3),
then the system notifies the provider to review the results in EPIC through the best practice
advisory (BPA), which are reminder tools within EPIC electronic health records that provide
clinical decision support. Once alerted of positive depression and/or distress scores by the BPA,
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the provider will document an action plan and talk to the patient. Referral options under EPIC
include: “Referral to Social Work”, “Referral to Psychiatry”, and “Referral to Psychology''.
Other action plans may not require referral but instead include: continued care with an existing
mental health provider, discussing pertinent distress symptoms and providing counseling, and
reviewing and adjusting medications. BPA will notify the provider if the patient has answered
the self-harm question with an exclamation mark. Depression scores that are considered
moderately severe and severe are also represented with a bright, yellow icon. If the patient has a
positive self-harm response, then either a social worker or a nurse will stay with the patient until
the patient is transferred to the Emergency Department (Figure 1).

Data Analysis
Statistical analyses were conducted with the SAS 9.4 statistical software. Baseline data
were stratified on variables such as age, sex, race, cancer center, time since cancer diagnosis, and
cancer type. Since the PHQ-9 and the distress questionnaire allowed patients to input exact,
numerical responses to all questions, we based each category of depression and distress criteria
on appropriate thresholds for validated score ranges: For example, depression and distress scores
were categorized into their appropriate criteria (minimal, mild, moderate, moderately severe, and
severe depression and negative and positive distress, respectively) and were descriptively
analyzed as categorical variables across all previously mentioned covariates. The threshold for
the variable, “time since a patient's first cancer diagnosis”, was determined at six months since
the onset of the COVID-19 pandemic terminated data collected after 11 months. Hence, all
patients in the sample did not have a period of 1-year post initial cancer diagnosis. Statistical

13

comparisons of categorical depression and distress scores were performed with the Fisher Exact
test with a Monte Carlo simulation.
For analytical purposes, the characteristic “Referral to Social work”, was categorized as a
dichotomous variable with two outcomes: Patients referred to social work or treated with a
different intervention. As a variable, “Referral to Social Work” encompassed numerous related
treatment options, which included, “Referral to Social work; Discussed pertinent distressing
symptoms and provided counseling”, “Medications reviewed and added or adjusted as needed;
Referral to Social work”, and simply, “Referral to Social work”. Social work was an intervention
of interest to the study since OCM purports the need for integrated, multidisciplinary cancer care
that includes psychosocial work plans produced by social workers.
We used simple and multivariate unconditional logistic regression models to identify key
exposure variables and predictors on the binary outcome of self-harm. The primary exposure
variables were categorical scores of depression. Key covariates included age, sex, race, cancer
center, time since cancer diagnosis, cancer type, and distress scores. The binary outcome of selfharm was split into two categories depending on the patients’ answer to the last question of the
PHQ-9 questionnaire—"Thoughts that you would be better off dead, or thoughts of hurting
yourself in some way?"—and their respective PHQ-9 score. If the patient scored a 0 on the last
PHQ-9 question, then they were not at risk of self-harm or suicide; however, if an individual
answered a 1, 2, or 3, then the patient was considered high-risk of self-harm and suicidal
thoughts. The reference categories for age, sex, race, cancer center, time since cancer diagnosis,
cancer type were patients aged 25-44 years old, males, White or Caucasians, Smilow Breast
Cancer Center, patients with less than six months since cancer diagnosis, and all other cancers,
respectively. The reference variables for depression and distress criteria were negative
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depression and negative distress, respectively. Discovery modeling was performed in a 50%
split of the total sample, creating two randomly assigned discovery and validation datasets
compared across selected parameter estimates to test for equivalence, reliability, and external
validity. The sensitivity and specificity were also determined for each multivariate regression
model. Additionally, the goodness of fit of each multivariate logistic model was estimated with
the Hosmer-Lemeshow test.

Results:
Characteristics of Patients
A total of 6,192 patients from Smilow Breast Cancer Center, Torrington Care Center, and
Guilford Care Center were part of the study from April 2019 to March 2020, with 49.3% of
patients from Smilow, 21.3% from Torrington, and 29.3% from Guilford. The mean age was
66.8 + 13.0 years, and 81.7% of participants were women (Table 1). There were more females
than males in the sample; more than half of the participants were admitted to Smilow, where
98.9% of survey respondents were female. The most common reasons for non-participation in
the distress and depression screenings included language barriers, technology issues, and general
refusal. Therefore, 5,396 patients completed the distress survey, and 5,576 patients completed
the PHQ-9 questionnaire. The top six most reported cancer subtypes across all three cancer
centers were: Breast cancer, chronic lymphocytic leukemia, malignant melanoma, prostate
cancer, myeloma, and colon cancer. These six cancer subtypes accounted for 64.8% of all
reported cancers. The most reported cancer subtype was breast cancer, which accounted for
55.5% of all cancer diagnoses. 82.6% of all participants were White, and most patients were
diagnosed within the past 6 months, with 11.5% diagnosed more than 6 months prior (Table 1).
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Distribution of Depression Scores
The mean and median score of the total PHQ-9 score was 0.81 + 2.73 and 0, respectively.
Outcomes for each survey were skewed to the right since the majority of patients reported low
scores of 0 or 1 on the PHQ-9 survey: 79.2% of study participants had a total PHQ-9 score of 0.
The highest reported depression score was 27 with a cumulative frequency of 0.04%. Also,
16.1%, 1.67%, 1.69%, 0.92%, and 0.34% of cancer patients were in the minimal, mild, moderate,
moderately severe, and severe categories of depression, respectively. (Table 2)
A total of 94.7% of study participants had a PHQ-2 score < 3, which does not require an
intervention from the provider (Table 2 and 3). The remaining 5.30% of participants scored a 3
or higher on the PHQ-2 survey and had to complete the PHQ-9, which necessitated intervention.
(Table 2). 52.6% of patients aged 45-64 and 36.8% of patients aged 65-84 reported severe
depression compared to 10.5% of 25-44 year olds and 0% of 85+ year olds with severe
depression (p-value=<0.001). Additionally, 78.9% of females reported severe depression
compared to 21.1% of males (p-value=<0.001) with severe depression. 47.4% of patients with
breast cancer were severely depressed compared to 5.26% with myeloma and 47.4% with other
cancer types who were severely depressed (p-value=<0.001). 84.2% of patients with less than 6
months since diagnosis reported serve depression compared to 15.8% of patients with more than
6 months since diagnosis who were severely depressed. (p-value=<0.001). (Table 5)

Distribution of Distress Scores
The mean and median score of the distress survey was 1.79 + 2.32 and 1.00, respectively
(Table 4). Similar to the non-parametric distribution of depression scores, most of the distress
were skewed to the right: 45.3% of participants had a total distress score of 0. Furthermore,
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81.4% of cancer patients had a negative distress score (distress ≤ 4). Additionally, 18.6% of
patients reported positive distress scores. The highest reported distress score was a 10 with a
frequency of 0.73%. (Table 3)
48.9% of patients who were 45-54 year olds reported positive distress compared to 7.41%
of patients aged 25-44 year olds, 39.2% of patients aged 65-84 year olds, and 4.50% of patients
who were 85+ year olds with positive distress. There were 89.7% females who reported positive
distress scores compared to 10.3% males with positive distress. Additionally, 85.0% of patients
who were White had positive distress compared to 5.52% patients who were Black or African
American, 1.91% of Asian patients, 3.20% of other races, and 4.34% of patients who refused to
disclose their race with positive distress (p-value=<0.001). There were 30.8% breast cancer
patients who reported positive distress compared to 30.8% patients suffering from other cancer
types, 1.50% chronic lymphocytic leukemia patients, 1.30% malignant melanoma patients,
0.50% prostate cancer patients, and 0.10% colon cancer patients with positive distress. There
were 87.1% of patients with less than 6 months since their cancer diagnosis who had positive
distress compared to 12.9% of patients more than 6 months since their cancer diagnosis with
distress. There were 68.2% of patients seen at Smilow Breast Cancer Center with positive
distress compared to 10.0% and 21.8% of patients to Torrington and Guilford with positive
distress, respectively. (Table 6)

Distribution of Referral to Social Work
In total, there were 192 patients who were referred to social work per OCM
recommendations, which comprised 15.2% of all interventions administered for distress and
depression. Moreover, all 257 patients who were at risk of depression and/or 999 patients at risk
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of distress were referred to appropriate interventions, which included, “Counseling provided to
patient, no mental health referral required”, “Medications reviewed and added or adjusted as
needed”, and “Continue care with existing mental health provider; Discussed pertinent
distressing symptoms and provided counseling”. Therefore, there was a 100% intervention rate
in this program.

Reports of Positive Self-Harm
In total, 62 oncology patients had positive self-harm responses, which comprised 1.00%
of the total sample. Out of the 712 patients who answered the last question on the PHQ-9, 8.71%
of patients tested positive for self-harm. Positive self-harm scores were reported across all
depression and distress criteria and recorded across all age groups, sexes, races, cancer centers,
times since cancer diagnosis, and cancer types. Additionally, 33.3%, 20.4%, and 12.8% of
patients with severe, moderately severe, and moderate levels of depression reported positive selfharm scores. Also, 14.1% of patients with positive distress reported positive self-harm scores.
Patients with the highest frequency of positive test scores were aged 25-44 (14.8%). Also, 10.5%
of males had positive self-harm scores compared to 8.10% of females. (Table 7)

Unconditional Logistic Regression Analysis
The simple, unadjusted logistic regression model looked at each predictor variable
separately and analyzed their individual effects on self-harm. For the unadjusted logistic
regression model, the parameter estimates were similar for the discovery and validated models,
and the parameter estimates for the validated model were reported. Hence, the unadjusted model
is a reliable predictor of self-harm.
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The multivariate analysis was also conducted for both discovery and validation datasets
as well as sensitivity and specificity analyses. However, the groups were discrepant in terms of
the key predictors selected in their respective stepwise, multivariate logistic regression models.
The discovery model selected for patients who refused to disclose their race, people of other
races, patients aged 45-64, patients with positive distress, and patients with prostate cancer;
however, patients of other races were not a significant predictor in the stepwise regression for the
discovery model. Meanwhile, the validated model selected for female patients, patients seen at
Guilford, patients seen at Torrington, patients with prostate cancer, and patients suffering from
severe and moderately severe depression. In the discovery regression model, prostate cancer is
more correlated with the outcome and had a significant p-value; however, in the validated
stepwise regression model, prostate cancer was a not statistically significant predictor (pvalue=0.06) of self-harm. Additionally, In the validated stepwise logistic regression model, the
p-value was not statistically significant for female patients (p-value=0.13) and was not
statistically significant for patients seen at Torrington (p-value=0.14). Since the selected
variables and the parameter estimates for the discovery and validation dataset were different, the
validated model should be interpreted with caution.
The p-value for the Hosmer and Lemeshow test was 0.87 for the validated model,
meaning that we can reject the null hypothesis and conclude that the model accurately predicts
the probability of self-harm. However, the stepwise logistic regression for the validated dataset
may not indicate the model’s reliability to predict self-harm due to the discrepant parameter
estimates observed during the discovery modeling.
Both the validation and discovery data tests had high specificity and low sensitivity
values. The specificity, or the true negative rate, is the proportion of true negative responders to
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the self-harm question who had a negative result on the last question on the PHQ-9 survey. The
specificity for the validated and discovery models were 99.4% and 100%, respectively. On the
other hand, the sensitivity, or the true positive rate, is the proportion of true positive responders
who had a positive result to the last question on the PHQ-9. The sensitivity for the validated and
the discovery models were 11.8% and 0.00%, respectively. The parameter estimates of
sensitivity and specificity are different in both models. However, if only considering the
validated dataset, the multivariate regression model was able to identify a positive result for
11.8% of people suffering from harmful or suicidal thoughts and find a negative result for 99.4%
of patients who did not suffer from self-harm or suicidal thoughts.
In the validated, multivariate stepwise logistic regression, the statistically significant
predictors were patients seen at Guilford, patients suffering from severe depression, and patients
with moderately severe depression. Compared to patients seen at Smilow and Torrington,
patients seen at Guilford had 0.17 lower odds (CI: 0.05-0.66) of reporting a positive self-harm
response. Compared to patients with minimal, mild, moderate depression, patients with
moderately severe depression had 3.72 (CI: 1.24-11.2) higher odds of reporting self-harm. Also,
compared to patients with minimal, mild, moderate depression, patients with severe depression
had 8.23 (CI: 1.72-39.3) higher odds of reporting self-harm. (Table 8)

Discussion:
This analysis examined the prevalence of depression and distress scores in oncology
patients who participated in the new, electronic workflow piloted by Smilow Cancer Hospital.
This analysis also identified predictors for self-harm and suicidal thoughts as an effort to
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understand if this outcome is predicted by depression while considering key covariates like age,
sex, race, cancer center, time since cancer diagnosis, distress, and cancer type.
Although the majority of patients reported negative depression and distress scores, it is
imperative to focus on patients who reported positive distress and PHQ-9 scores since they
require timely and immediate action plans from providers. Previous meta-analyses have
indicated variability in prevalence rates of depression that range from 0% to 46% for cancer
patients.25 In this study, 81.4% of patients reported negative distress. Moreover, 94.7% of
patients reported negative depression since their PHQ-2 score was less than 3—this also includes
the depression criteria for minimal depression (PHQ-9 score between 1-4), which does not
necessitate provider intervention. 18.6% of patients had positive distress, and 5.30% had positive
PHQ-9 Scores indicating depression. For those with positive PHQ-9 scores, 1.67%, 1.69%,
0.92%, and 0.34% had mild, moderate, moderately severe, and severe depression, respectively.
According to existing literature, prevalence estimates for major depression—which includes
moderate, moderately severe, and severe depression—and minor depression—which includes
mild and minimal depression—are 15% and 10% in cancer patients, respectively.26 In this
program, 2.95% had major depression, and 17.8% had minor depression. Although this study had
lower rates of major depression and higher rates of minor depression, it is crucial to prioritize
patients with moderate, moderately severe, and severe depression since it has been indicated that
major depression can lead to worse outcomes.
Patients who comprised the highest percentages of severe depression were patients aged
45-64 years old, were females, were White, and had breast cancer. Previous literature suggests
that depression is most common in pancreatic and lung cancers8; however, breast cancer patients
in our study had the highest frequencies of depression across all depression criteria. This finding
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could be attributed to the fact that 98.9% of patients who completed the distress and depression
surveys at Smilow Breast Cancer were women. Since most of the sample was comprised of
female breast cancer patients, future studies should examine a more diverse sample.
Previous work has indicated that mental illness is a key predictor of suicidality in cancer
patients and that a strong relationship exists between depression and suicide risk.13 In fact, more
than 90% of people who committed suicide have depression or another underlying mental
illness.27 Previous work indicated that depressive episodes, pain, and a lack of social network are
root causes for suicide ideation in cancer patients.28 In our study, the multivariate regression
model indicated that patients who were at risk of self-harm and suicidal thoughts were those with
prostate cancer, patients with severe depression, and patients with moderately severe depression.
Compared to negative, minimal, mild, and moderate depression, the odds ratio of reporting selfharm scores was 3.72 (CI: 1.24-11.2) for moderately severe depression and 8.23 (CI:1.72-39.3)
for severe depression. Although these findings correspond with current literature regarding
depression as a risk factor for suicide, they do not account for other important factors such as
poor social support, hopelessness, advanced cancers, and delirium on self-harm risk.28 Moving
forward, Smilow Cancer Hospital should consider the effects that moderately severe and severe
depression have on self-harm and encourage providers to recognize the importance of
maintaining a supportive rapport with patients while treating major depressive symptoms
appropriately. The multivariate regression model indicated that the last question on PHQ-9 had a
high specificity (99.4%) and lower sensitivity (11.08%), implying that the last question,
"Thoughts that you would be better off dead, or thoughts of hurting yourself in some way?", was
able to detect true negative responders given depression as the primary exposure. Current
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literature notes that the diagnostic sensitivity of PHQ-9 scores >10 has a sensitivity of 88%, but
more research is needed regarding the diagnostic validity of the last question.29
When tethered with depression screening, routine distress screening of cancer patients
can improve overall care when accompanied with psychosocial treatment. Previous studies
indicated that 25-30% of newly diagnosed cancer patients have high levels of distress.30 In our
study, 87.1% of cancer patients diagnosed in the past 6 months had a positive distress score
compared to 12.9% of cancer patients with more than 6 months since their initial diagnosis.
Hence, it is critical for physicians to appropriately refer these patients to holistic, patient-centric
treatment options like social workers. Social workers are essential for addressing numerous
psychosocial interventions and are at the forefront of developing plans that pinpoint patients’
distress.
Although patients may have a negative distress score or a negative depression score, they
could still be at risk of self-harm and suicidal thoughts. Our results indicate that 5.58% of
patients with negative distress and 8.11% of patients with minimal depression had positive selfharm responses. To that extent, depressive symptoms, even mild ones, can still deleteriously
impact a patient's cancer trajectory and decrease their quality of life, ultimately contributing to
suicide.13 Moreover, incident depression holds tremendous clinical value in early detection of
suicide and therefore should not be overlooked by providers.13 Studies have also indicated that
actual suicide rates are higher in men than in women 31, which shed insight into the reported
frequencies of positive self-harm by males and females in cancer patients, which were 10.5% and
8.10%, respectively. Previous findings have also indicated that the first six months after a cancer
diagnosis is an incredibly stressful period that can increase the risk of suicide in cancer
patients.32 Unsurprisingly, 87.1% of Yale cancer patients with less than 6 months since their
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diagnosis suffered from positive distress compared to 12.9% of Yale cancer patients with more
than 6 months since diagnosis. However, the difference in self-reported self-harm scores was
marginally different between patients who had less than 6 months since diagnosis (7.73%) versus
patients who had more than six months (8.95%). Previous work has indicated that suicide rates in
cancer patients decrease years after diagnosis; nevertheless, it is imperative that physicians
adequately assess suicidal tendencies during the early, critical period of elevated suicidal
ideation.13 Although physicians may not be able to prevent the chronic medical effects of cancer,
they have a responsibility to prevent psychological and psychosocial fall-out. Hence, early
depression and distress screenings and effective treatments are critically important for reducing
the cost associated with cancer and improving cancer patients’ quality of life.
Additionally, previous meta-analyses have indicated that patients with prostate cancer
have significantly higher suicide rates per 100,000 person-years compared to other cancers,
which parallels the high percentage of patients with prostate cancer (44.4%) reporting positive
self-harm in this study.33 Existing literature has also indicated that patients who have been
diagnosed with prostate, lung, colon, and breast cancer were also more likely to report positive
scores of self-harm.34 In our study, 4.00% of patients with colon cancer, 8.68% of patients with
breast cancer, 4.00% of patients with myeloma reported positive scores of self-harm.
Additionally, 6.25% of Yale patients with chronic lymphocytic leukemia and 8.23% patients
with other cancers also reported positive self-harm scores. Existing literature demonstrated that
patients with breast cancer had an elevated risk of suicidality compared to patients with other
cancers and that elderly men with prostate cancer and men with myeloma were also at increased
risk of self-harm.35 In a prospective study carried out in cancer patients in the UK, patients who
reported thoughts of self-harm were significantly younger than the rest of the cohort.34 Similarly,
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14.8% of Yale cancer patients aged 25-44 years old reported positive self-harm scores, which
was higher than the reported positive self-harm scores by 45-64 year olds (6.46%), 65-84 year
olds (8.75%), and patients 85+ years of age (11.5%). Ultimately, future studies at Yale New
Haven Health should also gauge the impact of chronic lymphocytic leukemia on self-harm as
well as other social factors, such as marital status, religious beliefs, and family support on suicide
risk.
The study’s greatest strength was its ability to refer everyone at risk of depression and
distress to appropriate interventions. The EPIC workflow and the BPA notification system
enabled physicians to create action plans when notified of a positive depression and/or distress
score through the electronic workflow. Furthermore, the Oncology Care Model encouraged the
use of social work to treat numerous facets of patients’ emotional and psychosocial repertoire.
15.2% of patients who received interventions were referred to social work; although some action
plans may not elicit the help of a social worker, it is important that physicians recognize the
importance of social workers in the multidisciplinary framework of medicine and the social
worker’s role in improved health outcomes. Additionally, the brevity of both the distress and
depression surveys assures greater completion of data while reducing participant fatigue. As
such, the electronic surveys were quick and straightforward to fill out, taking approximately 5
minutes to complete.
There are several limitations regarding the study’s design and timeframe. Given that this
study was a pilot program implemented for a short period of 11 months, data regarding followups and the effectiveness of specific psychological or lifestyle interventions were not collected.
In the same regard, data on lower total scores of PHQ-9 or distress do not exist, and conclusions
cannot be drawn on the overall effectiveness of the standardized, electronic workflow for
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depression and distress. Also, the program was primarily composed of White women, which
affects the generalizability of these findings.
Every participant has a vital role to play in improving patient health efficiently and
effectively. Although PROs are helpful in clinical management, it has been challenging to
implement in clinical settings: Time, expenses, and adequate assessment measures are several
significant burdens preventing the widespread use of PROs in routine healthcare practice. When
considering PRO implementation programs, it is crucial to monitor and adjust for these caveats
and setbacks, especially within their early phases. Factors affecting the implementation of these
PROs include overwhelmed physicians, technology and software issues, confusion about the
workflow, and lack of resources for positively screened patients. Additionally, patients who
completed the questionnaires experienced several pros and cons with the new electronic
workflow. Patients also voiced a preference for the iPad over paper since the latter method was
tedious, burdensome, and required interpretation of a nurse practitioner. In the future, special
circumstances should be considered in the assessment of distress and depression, such as cultural
sensitivity, language barriers, and provisions for people with cognitive impairments.
Looking forward, the leadership at Smilow Cancer Center should consider collecting
PRO data as frequently as possible without overburdening patients. In the case of the PHQ2/PHQ-9 and distress questionnaires, the overarching goal of this new electronic workflow is to
understand if a patient’s depression and/or distress changed from baseline to a future point in
time after administration of a particular intervention. Unfortunately, as of December 2019, the
SARS-CoV-2 pandemic has temporarily halted this new electronic screening program. Once
Smilow Cancer Hospital reinitiates this pilot study, leadership at Yale New Haven Health can
assess if PROs and provider interventions and action plans improved patients’ distress and
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depression symptoms. Moreover, it is important to employ personnel who can help patients
complete the distress and depression surveys to increase compliance and reduce missing data
without influencing their response.
Furthermore, the SARS-CoV-2 global pandemic has emphasized the need for PROs and
precision medicine for cancer patients: the onslaught of a severe, contagious respiratory illness
has increased the need for telemedicine and remote monitoring of patients. As patients become
further removed from their physicians, patient-centric care carries more importance; therefore,
clinicians need to administer appropriate interventions despite resource constraints so that cancer
patients can improve their distress and depression symptoms. Consequently, cancer hospitals
should incorporate PROs for distress and depression screening in electronic questionnaires that
can be done at home to assess for mental health during these troubling times.
In sum, PROs are incredibly important for improving quality of life since physicians may
mistakenly dismiss severe depressive symptoms as normal emotional responses to cancer. PROs
can address the issue of therapeutic nihilism, which prevents clinicians from differentiating
clinical depression from normal sadness. The electronic screening workflow is the right step
towards increasing PRO compliance in cancer patients.
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List of Tables:
Table 1: Patient Baseline Characteristics (N=6,192)

Characteristic

Age (years), mean+ SD

Na

N%

66.8 + 13.0

Sex
Male

1264

18.3%

Female

5656

81.7%

5715

82.6%

432

6.24%

Asian

133

1.92%

Other

268

3.87%

Patient Refused

372

5.38%

Breast Cancer

3843

55.5%

Chronic lymphocytic
leukemia

196

2.83%

Malignant Melanoma

123

1.78%

Prostate Cancer

126

1.82%

Myeloma

101

1.46%

Colon Cancer

93

1.34%

Race

White or Caucasian
Black or African
American

Cancer Type

28

Other cancers

2439

35.2%

More than 6 months
since diagnosis

795

11.5%

Less than 6 months
since diagnosis

6126

88.5%

Smilow

3414

49.3%

Torrington

1477

21.3%

Guilford

2030

29.3%

Time Since Diagnosis

Site

Table 2: Distribution of PHQ-9 Scores (N=5,576)

Characteristic
PHQ-9 Scores, mean+
SD

Na

N%

0.81 + 2.73

PHQ-Scores

0

4417*

79.2%*

1

421*

7.55%*

2

441*

7.91%*

3

18

0.32%

4

19

0.34%

5

20

0.36%

29

6

20

0.36%

7

23

0.41%

8

12

0.22%

9

18

0.32%

10

19

0.34%

11

21

0.38%

12

20

0.36%

13

14

0.25%

14

20

0.36%

15

11

0.20%

16

16

0.29%

17

11

0.20%

18

9

0.16%

19

4

0.07%

20

5

0.09%

21

6

0.11%

22

3

0.05%

23

2

0.04%

24

3

0.05%

30

25

0

0.00%

26

0

0.00%

27

2

0.04%

No depression

4417

79.3%*

Minimal

899

16.1%*

Mild

93

1.67%

Moderate

94

1.69%

Moderately Severe

51

0.92%

Severe

19

0.34%

Categories of
Depression

*Also equivalent to a PHQ-2 score less than 3

Table 3: Distribution of Distress Scores (N=5,396)

Characteristic
Distress Scores, mean+
SD

Na

N%

1.79 +2.32

Distress Scores

0

2435

45.3%

1

717

13.4%

2

681

12.7%

3

539

10.0%

31

4

247

4.60%

5

253

4.71%

6

143

2.66%

7

160

2.98%

8

114

2.12%

9

43

0.80%

10

39

0.73%

11

0

0.00%

12

0

0.00%

13

0

0.00%

14

0

0.00%

Negative Distress

4327

81.4%

Positive Distress

999

18.6%

Categories of Distress

Table 4: Referral to Social Work (N=192)

Characteristic

Na

N%

192

15.2%

Referral Rate

Social Work

32

Other interventions

1064

84.8%

25-44

26

13.5%

45-64

93

48.4%

65-84

72

37.5%

85+

1

0.52%

Age (years)

Sex
Male

17

8.85%

Female

175

91.2%

Race

White

128

78.5%

15

9.20%

Asian

4

2.45%

Other

8

4.91%

Patient Refused

8

4.91%

Breast Cancer

126

65.6%

Chronic lymphocytic
leukemia

0

0.00%

Malignant Melanoma

1

0.52%

Prostate Cancer

0

0.00%

Black or African
American

Cancer Type

33

Myeloma

0

0.00%

Colon Cancer

2

1..04%

63

1.04%

More than 6 months
since diagnosis

47

24.5%

Less than 6 months
since diagnosis

145

75.5%

Smilow

151

78.7%

Torrington

21

12.5%

Guilford

17

8.85%

Severe

5

2.60%

Moderately Severe

13

6.77%

Moderate

17

8.85%

Mild

6

3.13%

Minimal

58

30.2%

No depression

93

48.4%

102

53.1%

Other cancers

Time Since Diagnosis

Site

Depression Scores

Distress Scores

Positive Distress

34

Negative Distress

90

46.9%

21

28.0%

54

72.0%

Answer to Self Harm
Question
Positive

Negative

Table 5: Description of Sample by Depression Score Categories (N=5,576)

Depression
Scores

No
depressi
on
(N, %)

Minimal
depressio
n (N, %)

Mild
depression
(N, %)

Moderate
depression
(N, %)

Moderately
severe
depression
(N, %)

25-44

184
(4.17%)

59
(6.56%)

7 (7.53%)

9 (9.57%)

4 (7.84%)

2 (10.5%)

45-64

1580
(35.8%)

371
(41.3%)

41 (44.1%)

34 (36.2%)

25 (49.0%)

10 (52.6%)

65-84

2286
(51.8%)

493
(44.8%)

35 (37.6%)

46 (48.9%)

20 (39.2%)

7 (36.8%)

85+

367
(8.31%)

66
(7.34%)

10 (10.8%)

5 (5.32%)

2 (2.62%)

0 (0.00%)

Male

858
(19.4%)

115
(12.8%)

15 (16.1%)

12 (12.7%)

9 (17.7%)

4 (21.1%)

Female

3558
(80.6%)

784
(87.2%)

78 (83.8%)

82 (87.2%)

42
(82.35%)

15 (78.9%)

73 (78.5%)

66 (70.2%)

38 (74.5%)

13 (68.4%)

14 (15.1%)

9 (9.57%)

4 (7.84%)

1 (5.26%)

Characteristic

Severe
Depression
(N, %)

P Value (Fisher Exact
Test)

Age (years)

<0.001

Sex

<0.001

Race
White or
Caucasian

3721
(84.2%)

Black or
African
American

237
(5.37%)

728
(81.0%)

73
(8.12%)

<0.001

35

Asian

69
(1.56%)

23
(2.56%)

2 (2.15%)

5 (5.32%)

2 (3.92%)

0 (0.00%)

Other

132
(2.99%)

40
(4.45%)

2 (2.15%)

11 (11.7%)

5 (9.80%)

3 (15.8%)

Patient Refused

258
(5.84%)

35
(3.89%)

2 (2.15%)

3 (3.19%)

2 (3.92%)

2 (10.5%)

Cancer Type

<0.001
2332
(52.8%)

527
(34.3%)

53 (57.0%)

57 (60.6%)

24 (47.1%)

9 (47.4%)

Chronic
lymphocytic
leukemia

147
(3.33%)

14
(1.56%)

2 (2.15%)

0 (0.00%)

0 (0.00%)

0 (0.00%)

Malignant
Melanoma

76
(1.72%)

11
(1.22%)

0 (0.00%)

1 (1.06%)

0 (0.00%)

0 (0.00%)

Prostate
Cancer

87
(1.97%)

18
(2.00%)

1 (1.08%)

3 (3.19%)

2 (3.92%)

0 (0.00%)

Myeloma

69
(1.56%)

13
(1.45%)

1 (1.08%)

2 (2.13%)

0 (0.00%)

1 (5.26%)

Colon Cancer

51
(1.15%)

8 (0.89%)

1 (1.08%)

1 (1.06%)

0 (0.00%)

0 (0.00%)

1655
(37.5%)

308
(34.3%)

35 (37.6%)

30 (31.9%)

25 (49.0%)

9 (47.4%)

Breast Cancer

All other
cancer types
Time Since
Diagnosis

<0.001

More than 6
months since
diagnosis

552
(12.5%)

173
(19.2%)

6 (6.45%)

6 (6.38%)

12 (25.5%)`

3 (15.8%)

Less than 6
months since
diagnosis

3865
(87.5%)

726
(80.8)

87 (93.6%)

88 (93.6%)

39 (76.5%)

16 (84.2%)

Smilow

2035
(46.1%)

540
(60.1%)

59 (63.4%)

59 (62.8%)

32 (62.8%)

11 (57.9%)

Torrington

1053
(23.8%)

76
(8.45%)

8 (8.60%)

13 (13.8%)

9 (17.7%)

3 (15.8%)

Guilford

1329
(30.1%)

283
(31.5%)

26 (28.0%)

22 (23.4%)

10 (19.6%)

5 (26.3%)

Site

36

Table 6: Distribution of Distress Scores (N=5,396)

Distress
Scores

Characteristic

Negative
Distress
(N, %)

Positive
Distress
(N, %)

Age (years)

P-value

<0.001

25-44

202
(4.62%)

72 (7.41%)

45-64

1549
(35.4%)

488 (48.9%)

65-84

2254
(51.6%)

392 (39.2%)

85+

367
(8.39%)

45 (4.50%)

Sex

<0.001

Male

938
(21.5%)

103 (10.3%)

Female

3433
(78.5%)

896 (89.7%)

Race

<0.001

White
Black or African
American

2022
(83.04%)

1647 (85.0%)

135
(5.54%)

107 (5.52%)

Asian

40 (1.64%)

37 (1.91%)

Other

77 (3.16%)

6 (3.20%)

161
(6.61%)

84 (4.34%)

Patient Refused

Cancer Type

Breast Cancer

<0.001
2191
(50.1%)

308 (30.8%)

37

Chronic lymphocytic
leukemia

148
(3.39%)

15 (1.50%)

81 (1.85%)

13 (1.30%)

100
(2.29%)

5 (0.50%)

Myeloma

83 (1.90%)

5 (0.00%)

Colon Cancer

69 (1.58%)

1 (0.10%)

1700
(38.9%)

308 (30.8%)

Malignant Melanoma

Prostate Cancer

All other cancer
types

Time Since Diagnosis

<0.001

More than 6 months
since diagnosis

627
(14.3%)

129 (12.9%)

Less than 6 months
since diagnosis

3745
(85.7%)

870 (87.1%)

Site

<0.001

Smilow

1870
(42.8%)

681 (68.2%)

Torrington

1112
(25.4%)

100 (10.0%)

Guilford

1390
(31.8%)

218 (21.8%)

Table 7: Unadjusted Associations Between Study Variables and Positive Self-harm Scores (N=62)

Characteristic

Na

n (%) with positive
self-harm scores

Unadjusted Odd
Ratios

54

8 (14.8%)

1.00

Age (years)

25-44

38

45-64

263

17 (6.46%)

0.63 (0.16-2.43)

65-84

323

30 (8.75%)

0.66 (0.18-2.46)

85+

61

7 (11.5%)

0.53 (0.08-3.49)

Female

568

46 (8.10%)

0.61 (0.28-1.33)

Male

153

16 (10.5%)

1.00

Black or
African
American

60

3 (5.00%)

0.37 (0.05-2.84)

Asian

17

3 (17.7%)

3.46 (0.67-18.0)

Other

31

4 (16.1%)

1.48 (0.32-6.89)

Patient
Refused

26

6 (23.1%)

3.46 (0.88-13.6)

White or
Caucasian

587

45 (7.67%)

1.00 (1.00)

Breast
Cancer

334

29 (8.68%)

1.14 (0.54-2.41)

Chronic
lymphocytic
leukemia

16

1 (6.25%)

<0.001* (<0.001>999.9)

Malignant
Melanoma

11

0 (0.00%)

<0.001* (<0.001>999.9)

Prostate
Cancer

9

4 (44.4%)

10.4 (1.91-56.2)

Myeloma

25

1 (4.00%)

<0.001* (<0.001>999.9)

Colon Cancer

10

1 (4.00%)

1.73 (0.19-15.4)

Sex

Race

Cancer Type

39

Other cancers

316

26 (8.23%)

1.00 (1.00)

207

16 (7.73%)

0.91 (0.41-2.01)

514

46 (8.95%)

1.00

354

36 (10.2%)

1.00

81

14 (17.3%)

3.24 (1.39-7.54)**

286

12 (4.20%)

0.32 (0.12-0.89)**

18

6 (33.3%)

10.3 (2.11-49.9)**

Moderately
Severe

49

10 (20.4%)

6.84 (2.14-21.9)**

Moderate

86

11 (12.8%)

2.85 (0.95-8.52)

Mild

79

3 (3.80%)

0.40 (0.05-3.23)

Minimal

185

15 (8.11%)

2.08 (0.79-5.46)

No depression

304

17 (5.59%)

1.00

Positive Distress

255

36 (14.1%)

2.16 (1.06-4.40)**

Negative Distress

466

26 (5.58%)

1.00

Time Since
Diagnosis
More than 6
months since
diagnosis
Less than 6
months since
diagnosis

Site

Smilow

Torrington

Guilford
Depression
Scores

Severe

Distress Scores

*Large confidence intervals due to quasi-complete separation

40

**Statistically Significant

Table 8: Multivariable logistic regression model on Validated Dataset of Factors Associated with Thoughts of Self-Harm

Characteristic

Adjusted Odds Ratio (95% CI)

P-value

0.40 (0.12-1.32)

0.13

Torrington

2.18 (0.78-6.12)

0.14

Guilford

0.17 (0.05-0.66)

0.01*

Severe

8.23 (1.72-39.3)

0.01*

Moderately
severe

3.72 (1.24-11.2)

0.02*

7.55 (0.96-59.6)

0.06

Gender

Female

Site

Depression scores

Cancer Type

Prostate

*Statistically significant
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List of Figures:

Figure One: Current Workflow for Electronic Depression and Distress Process
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